Ben Hutchins

Ben Hutchins, PhD

Ben Hutchins, PhD joined Mythic Therapeutics in November 2020, building out technical operations capabilities, and driving CMC-related activities to deliver MYTX-011 to the clinic. He brings extensive technical and leadership experience in the process development, scale-up, technology transfer, and manufacturing of biologics, small molecules, and antibody drug conjugates (ADCs).

Prior to Mythic, Ben was Director of CMC at Editas Medicine, where he led the CMC team in the development of EDIT-301, an autologous cell-therapy medicine to treat sickle cell disease. Before that, Ben spent a decade at ImmunoGen, where he served as the director of CMC strategy, overseeing the development of numerous ADCs, and led the team responsible for designing the conjugation processes used to manufacture the ADCs.

Ben received his PhD in chemistry from Penn State and completed a postdoctoral fellowship at The Scripps Research Institute developing novel Fab conjugates through unnatural amino acid incorporation and conjugation.